Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 16, 2022, serves as a current report for Vivos Therapeutics, Inc., a Delaware corporation. The filing announces the issuance of a press release detailing financial results for the quarter ended March 31, 2022. The company is classified as an emerging growth company.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the full text of the press release containing these results is furnished as Exhibit 99.1 and is incorporated by reference, but the data itself is not present in the cover page text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the provided text. The filing acts as a notification of the results announcement rather than a detailed comparative analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information furnished (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 16, 2022) for specific Q1 2022 financial figures.
- Verify the company's emerging growth company status and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (VVOS) and exchange (NASDAQ) for current market data.
- Check subsequent filings for the full financial statements referenced in this 8-K.